GlaxoSmithKline plc (LON:GSK) insider Dominic Redfern bought 230 shares of the stock in a transaction on Thursday, April 13th. The shares were acquired at an average cost of GBX 1,639 ($21.16) per share, with a total value of £3,769.70 ($4,866.01).

Shares of GlaxoSmithKline plc (LON:GSK) traded up 0.58% on Friday, reaching GBX 1647.50. 9,217,003 shares of the company were exchanged. The firm’s market capitalization is GBX 80.50 billion. GlaxoSmithKline plc has a 12-month low of GBX 1,363.00 and a 12-month high of GBX 1,745.56. The company’s 50 day moving average is GBX 1,618.77 and its 200 day moving average is GBX 1,586.40.

Insider Buying and Selling by Quarter for GlaxoSmithKline plc (LON:GSK)

The firm also recently disclosed a dividend, which will be paid on Thursday, July 13th. Stockholders of record on Thursday, May 11th will be paid a GBX 19 ($0.25) dividend. This represents a dividend yield of 1.21%. The ex-dividend date is Thursday, May 11th.

ILLEGAL ACTIVITY NOTICE: “Dominic Redfern Buys 230 Shares of GlaxoSmithKline plc (GSK) Stock” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/05/19/glaxosmithkline-plc-gsk-insider-purchases-3769-70-in-stock-updated-updated-updated.html.

A number of analysts have commented on GSK shares. Liberum Capital reaffirmed a “buy” rating and set a GBX 1,900 ($24.53) target price on shares of GlaxoSmithKline plc in a report on Wednesday, February 8th. Goldman Sachs Group Inc set a GBX 1,850 ($23.88) price target on shares of GlaxoSmithKline plc and gave the company a “buy” rating in a report on Thursday, February 9th. Jefferies Group LLC boosted their price target on shares of GlaxoSmithKline plc from GBX 1,750 ($22.59) to GBX 1,780 ($22.98) and gave the company a “buy” rating in a report on Sunday, January 22nd. HSBC Holdings plc reaffirmed a “buy” rating and issued a GBX 1,970 ($25.43) price objective on shares of GlaxoSmithKline plc in a research report on Thursday, February 9th. Finally, Beaufort Securities reaffirmed a “buy” rating and issued a GBX 1,750 ($22.59) price objective on shares of GlaxoSmithKline plc in a research report on Friday, February 10th. Three equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and eight have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of GBX 1,743.36 ($22.50).

About GlaxoSmithKline plc

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Receive News & Stock Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related stocks with our FREE daily email newsletter.